Articles tagged with Drug Resistance
A growing global problem: Bacterial resistance to antibiotics is on the rise, with penicillin and macrolide antibiotics showing high levels of resistance. Telithromycin, a new ketolide antibiotic, has shown promise in combating treatment-resistant respiratory tract infections.
Researchers have identified a single gene on chromosome 7 of Plasmodium falciparum that makes the most deadly malaria parasite resistant to chloroquine. The pfcrt gene is associated with chloroquine resistance in parasite lines from Asia, Africa, and South America.
A study by University of Toronto researchers found that repeated exposure to azole drugs can lead to the development of drug-resistant yeast infections. About 75% of women between 18 and 35 will experience at least one yeast infection caused by Candida albicans, a common type of yeast fungus.
The study found that 27.2% of HIV patients were resistant to all three classes of drugs, while 29.1% had resistance to two classes and 21.9% were resistant to one. This underscores the importance of resistance testing for treatment decision-making in HIV clinical practice.
The international panel established recommendations for drug resistance testing in treating HIV failure and pregnant women. This guidance aims to optimize the use of these tests in designing effective drug therapies.
A preliminary study found that 38% of HIV-positive people in low-income hotels took over 90% of their medication, adhering well to combination anti-viral therapy. The researchers also discovered a close relationship between medication adherence and viral suppression, with levels of HIV doubling for every 10% of missed pills.
A new model predicts that expanding potent HIV therapies will limit infections and AIDS deaths, even with increased risk behavior and drug resistance. The model shows that treating more HIV-infected men will reduce infection rates and deaths below what they would be without treatment.
A new botulinum toxin type B medication has shown significant improvements in pain, disability, and disease severity in cervical dystonia patients. The treatment's benefits lasted for 12-16 weeks with no serious adverse side effects reported.
Researchers at St. Jude Children's Research Hospital found the gene MRP4 is responsible for drug resistance in HIV patients, leading to lower drug concentrations and increased virus replication. This discovery could lead to developing new therapies to fight HIV infection and other diseases.
Researchers at the University of Maryland Medical Center have discovered a cancer resistance protein that rapidly pumps out chemotherapy from breast cancer cells. This finding may lead to new strategies to reverse resistance to cancer-fighting drugs, improving treatment outcomes for patients.
Researchers suggest that genetic remnants of an ancient virus incorporated into human DNA may assist the AIDS virus in evading anti-drug treatments. Studies found that a specific enzyme from this endogenous virus gene can complement HIV-1 protease activity, making it resistant to current drugs.
Researchers at Brandeis University have pinpointed a genetic repressor that can transform diphtheria into a lethal parasite. The discovery could lead to a novel class of antibiotics that prevent bacterial virulence without inducing resistance.
A study by UNC researchers confirms the presence of mutated, drug-resistant human immunodeficiency virus in the semen of men taking antiviral medications. The study found that if men do not have adequate suppression of their virus, they are likely to shed drug-resistant strains of HIV in their genital secretions.
The international panel emphasizes that blood tests measuring HIV levels and CD4 cells should guide treatment decisions, rather than resistance testing. The panel also highlights the limitations of current resistance assays and recommends further epidemiological studies to monitor resistant strain prevalence.
Scientists have discovered that Helicobacter pylori resistance to metronidazole is caused by mutation in the rdxA gene. This gene codes for an enzyme that converts metronidazole into hydroxylamine, a mutagen and cancer-causing chemical.
Researchers found glioblastoma multiforme tumors resistant to procarbazine exhibited defects in mismatch repair, leading to drug resistance. The study may lead to more effective treatment of GBM, a common and virulent brain tumor.
Researchers at Johns Hopkins have found that spending more time and money on strict drug regimens saves money in the long run. The cost-effective strategy, called directly observed therapy (DOT), cures more people sooner and decreases the risk of developing TB germs resistant to treatment.